Trial
NCT01731990
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Peripheral Artery Disease
Intervention
Canakinumab (ACZ885)
Why stopped
The study got terminated based on result from primary endpoint analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29